natgillin/translations-raw huggingface dataset:
where R1, R3-R13 are as defined herein and R′ is a protection group such as a carbamate (such as methyl-, ethyl-, tert-butyl-, allyl-, or benzyl-carbamate); whereupon the compound of formula IE is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. Method 12 (for compounds of formula IF with R2=hydrogen) Deprotection of a compound of formula XV: 
Kn o gdje su R!, R*-R'* kako je to ovdje definirano a R' je protekcijska grupa kao karbamati (npr. metil-, etil-, tert-butil, alil-, ili benzil-karbamat); nakon čega se spoj formule ID izolira kao slobodna baza ili njezina sol kao farmaceutski prihvatljiva kisela dodatna njezina sol. Metoda 12 (spoj formule IF s R? = vodik).
The partition wall element as claimed in claim 3, wherein the interface of the partition wall element communicates with an interface of a gaming machine comprising a game sequence controller. 
Element pregradne stijenke sukladno patentnom zahtjevu 3, naznačen time, što sučelje (19) elementa pregradne stijenke (2) komunicira s međusklopom (29) automata (28) za igru koja sadrži kontroler slijeda igara.
receiving temperature data indicative of a temperature of the chamber; and selectively controlling two or more subsets of thermoelectric coolers in the plurality of thermoelectric coolers based on the temperature of the chamber; wherein selectively controlling the two or more subsets of thermoelectric coolers comprises operating each thermoelectric cooler in a first subset of thermoelectric coolers from the plurality of thermoelectric coolers at or near the point where the coefficient of performance is maximized (QCOPmax) by providing a current or voltage with amplitude corresponding to QCOPmax (ICOPmax, VCOPmax) when the temperature of the chamber is within a predefined steady state range including the set point temperature. 
zaprimanje (1000) podataka o temperaturi koji pokazuju vrijednost temperature u komori; i selektivno upravljanje (1002) za dva ili više TEH-podskupova od mnoštva TEH, na temelju vrijednosti temperature u komori; naznačen time, da selektivno upravljanje za dva ili više TEH-podskupova obuhvaća operativno djelovanje svakog pojedinog TEH u prvom TEH-podskupu od mnoštva TEH, na vrijednosti QCOPmax ili blizu nje, kada je temperatura u komori unutar raspona ravnomjernog stanja uključujući točku potrebne vrijednosti temperature.
side wall of the base body 
bočna stijenka osnovnog tijela 8
The process of claim 3, further comprising mixing the triacylglyceride-water mixture (12) with diatomic hydrogen (14) to form the triacylglycerides-water-diatomic hydrogen mixture (16). 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da nadalje obuhvaća miješanje smjese triacilglicerida i vode (12) s molekularnim vodikom (14) radi dobivanja smjese triacilglicerida, vode i molekularnog vodika (16).
A heterologous fusion protein of any one of claims 1 to 8 for use in the treatment of non-insulin dependent diabetes mellitus. 
Heterologni fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju dijabetes melitusa neovisnog o inzulinu.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is independently selected from-ORB, C1-3aliphatic, or halo. 
Cy! je izborno dalje supstituiran sa jednim do tri nezavisna R", pri čemu je svaki R* nezavisno izabran od -OR*, Cia alifatika ili halo.
A compound of formula (I): 
Spoj prema formuli (1): nI
removing unbound binding compound 
uklanjanje nevezanog spoja za vezanje;
The system of claim 9, wherein the vapor fraction from the high temperature/high pressure separator is fed to the fixed bed hydroconversion reactor system. 
Sustav u skladu s patentnim zahtjevom 29, naznačen time, da se parna frakcija iz separatora (40) visoke temperature / visokog tlaka dovodi u reaktorski sustav hidrokonverzije s fiksnim slojem (14).
Accordingly, the use of oxidizing agents such as HNO2, HNO3 or corresponding anhydrides thereof, or peroxodisulfates is likewise a subject matter of the present invention as is reaction Step c), especially when using as oxidizing agents such as HNO2 HNO3 or corresponding anhydrides thereof, or peroxodisulfates in the an alkylated aromatic hydrocarbon solvent, especially in toluene and xylene. 
Postupak u skladu sa zahtjevom 5, naznačen time, da se oksidacijski korak c provodi u prisutnosti oksidacijskog sredstva izabranog iz skupine koju čine HNO;, HNO; ili njihovi odgovarajući anhidridi, te peroksodisulfat, te pri čemu se kao otapalo koristi alklilirano aromatsko ugljikovodikovo otapalo kao što je toluen.
a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer, wherein said compound, pharmaceutically acceptable salt thereof or composition and second therapeutic agent are associated with one another. 
(1i) drugog terapijskog sredstva koje je korisno u liječenju ili prevenciji bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom, gdje su spoj, njegova farmaceutski prihvatljiva sol ili smjesa te drugo terapijsko sredstvo međusobno povezani, HR P20120317 T1
Number of individual IC50 
Broj međunarodne objave:
A compound, pharmacologically acceptable ester thereof, or pharmacologically acceptable salt thereof according to any one of claims 20 to 22, wherein, in the case where R7 represents a group having a hydroxy group (a hydroxy C1-C6 alkyl group, a hydroxyhalo C1-C6 alkyl group, a hydroxy C1-C6 alkoxy group, a hydroxy C1-C6 alkylcarbamoyl group, or a hydroxy C1-C6 alkylcarbamoyl C1-C6 alkyl group), the hydroxy group forms an ester bond with a C1-C6 alkanoyl group. 
Spoj, njegov farmakološki prihvatljiv ester ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 13 do 15, gdje, u slučaju gdje R7 predstavlja grupu koja ima hidroksi grupu (hidroksi C1-C6 alkil grupu, hidroksihalo C1-C6 alkil grupu, hidroksi C1-C6 alkoksi grupu, hidroksi C1-C6 alkilkarbamoil grupu ili hidroksi C1-C6 alkilkarbamoil C1-C6 alkil grupu), hidroksi grupa formira estersku vezu sa C1-C6 alkanoil grupom.
C3-7 cycloalkyl (said C3-7 cycloalkyl is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of C1-6 alkyl, halogen, hydroxyl C1-6 alkyl and halo C1-4 alkyl, and/or optionally form a fused ring with a benzene ring), or 
(iv) C3.; cikloalkil (navedeni C3; cikloalkil može biti supstituiran s 1, 2, 3 ili 4 supstituenti, koje se bira iz skupine koju čine C1.4 alkil, halogen, hidroksil C,4 alkil i halogenC;.4 alkil, i/ili može tvoriti kondenzirani prsten s benzenskim prstenom), ili
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
Plasma is isolated by centrifugation and frozen prior to analysis. 
Plazma je izdvojena centrifugiranjem, te zamrznuta prije analize.
reacting Compound 3 with Compound 6 to yield Compound 7: 
(b) reakciji Spoja 3 sa Spojem 6 kako bi se dobilo Spoj 7:
The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is in a form formulated for oral administration to a mammal. 
Farmaceutski pripravak prema zahtjevu 7, naznačen time da je navedeni farmaceutski pripravak u obliku pogodnom za oralno davanje sisavcu.
A pharmaceutical aerosol solution composition according to claim 1 wherein the overall formoterol degradation products level is lower than 10% w/w with respect to the theoretical formoterol fumarate content of 6mg/actuation and the residual level of formoterol fumarate is higher than 90% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 u kojem je ukupna razina degradacijskog produkta formoterola niža od 10% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 90% w/w prema njegovom početnom sadržaju.
The first one provides rigidity, whereas the latter allows moderate flexion deformity and slightly less extension. 
Prva daje rigidnost, dok potonja omogućava umjereni deformitet savijanja i nešto manje ekstenziju.
While not a part of the fuel, the aerosol generating means is in a conductive heat exchange relationship with the fuel element, and preferably abuts or is adjacent to the fuel element. 
Mada nije dio goriva, sredstvo za generiranje aerosola je u provodljivom odnosu za toplinsku razmjenu sa gorivim elementom, i poželjno dodiruje ili je blizu gorivog elementa.
The process of claim 9, wherein step (B)(iii) comprises the steps: 
Korak spajanja (e’) sadrži korake:
a compound of the formula (VIII) 
[C] spoj s formulom (VIII)
obtaining a context index indicating a context used in entropy encoding or decoding of the first critical value flag by using the context set index and the context offset. 
pribavljanje (2520) indeksa skupa konteksta koji se koristi u entropijskom dekodiranju zastavice prve kritične vrijednosti koja označava da li značajni koeficijent transformacije kojeg sadrži trenutni podskup ima vrijednost veću od prve kritične vrijednosti;
In some embodiments, the methods of this aspect additionally include executing program instructions on the one or more processors to automatically record the fraction of fetal of DNA as determined in (c) in a patient medical record, stored on a computer readable medium, for the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži izvršavanje programskih uputa u okviru jednog ili više procesora radi automatskog snimanja frakcije fetusne DNK koja je procijenjena u (c) u medicinski karton trudne osobe, kao 1 čuvanje na mediju koji može biti očitan od pomoću računala.
MI is a transition metal of group IB, or group 11 in the IUPAC nomenclature, 
M je prijelazni metal iz skupine Ip, ili skupine 11 u IUPAC-ovoj nomenklaturi,
X' is a second halide anion which is different from the first halide anion; and y is from 0.05 to 2.95. provided that: 
X ' je drugi anion halida koji je različit od prvog halidnog aniona 1 y je od 0, 05 do 2, 95. pod uvjetom da:
In some embodiments, the conditioning of the recipient includes a dose of total body irradiation (TBI), wherein the total body irradiation does not exceed 300 cGy. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da kondicioniranje primatelja uključuje dozu ukupnog tjelesnog zračenja (UTZ, engl. TBI), pri čemu ukupno tjelesno zračenje ne premašuje 300 cGy.
the filler is grinded asbestos-cement, preferably grinded asbestos-cement waste, in a ratio of up to 20% by weight, preferably between 12 and 20 % by weight based on the total amount of composite material, having the particle size between 2 micrometers and 0, 4 mm, and 
- < Je punjenje mljeveni azbestni cement, po mogućnosti mljeveni otpad azbestnog cementa, u udjelu do 20% težine, po mogućnosti između 12% 1 20% težine temeljeno na ukupnoj količini kompozitnog materijala, veličine čestica između 2 mikrometra i 0,4 mm, 1
8, FIG. 10 is a plan view of the sheet metal strip on termination of the stretching stage, 
je pogled s gornje strane na limenu metalnu traku na završetku faze rastezanja, slika 11
contacting the tissue or fluid sample with a monoclonal antibody of any one of claims 1-6 or fragment thereof that specifically binds to the protofibril form of B-amyloid peptide while showing minimal affinity to low molecular weight forms of B-amyloid peptide; and, 
stavljanju u kontakt uzorka tkiva ili tjelesne tekućine s monoklonskim protutijelom u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegovim fragmentom koji se specifično veže na protofibrilni oblik B-amiloidnog peptida dok pokazuje minimalni afinitet na niskomolekulske oblike B-amiloidnog peptida; i,
boronate derivatives of the above general formula XI: 
Datum objave europskog patenta:
each R5 is, independently, hydrogen, C1-4alkyl, imidazole, triazole, thiazole, pyridine, pyrimidine, oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, pyrrolidine, or triazole, or two R5 groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring, wherein each of said rings is optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two OC1-2alkyl groups. 
i svaki R5 je, nezavisno, vodik, C1-4alkil, imidazol, triazol, tiazol, piridin, pirimidin, oksetan, tetrahidrofuran ili tetrahidropiran, i svaka R5 grupa je izborno supstituirana s klorom, do tri atoma fluora, do dva C1-2alkila, CH2OH, CN, do dva OH, do dva OC1-2alkila, spirooksetana, pirolidina ili triazola, ili dvije R5 grupe zajedno s atomom dušika koji je između formiraju morfolin prsten, azetidin prsten, pirolidin prsten, piperidin prsten ili piperazin prsten; ili
The method according to claim 6, wherein the salt is a benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc salt. 
21.Farmaceutski prihvatljiva sol prema patentnom zahtjevu 19, naznačena time, što sol predstavlja sol benzatina, kloroprokaina, kolina, dietanolamina, etilendiamina, meglumina, prokaina, aluminija, kalcija, litija, magnezija, kalija, natrija, ili sol cinka.
The immunogenic polypeptide fragment of embodiment 31 or embodiment 32 wherein the E. coli AcfD (orf3526) protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-19. The immunogenic polypeptide fragment of any one of embodiments 31-33 wherein the immunogenic polypeptide further contains a deletion relative to the E. coli AcfD (orf3526) protein which increases solubility of the immunogenic polypeptide as compared to the E . coli AcfD (orf3526) protein. 
Imunogenski polipeptid prema bilo kojem od zahtjeva 1-6, naznačen time da imunogenski polipeptid nadalje sadrži brisanje relativno prema €. coli AcfD (orf3526) proteinu koje povećava topljivost imunogenskog polipeptida u odnosu na E. coli AcfD (0rf3526) protein pri čemu brisanje je uklanjanje značajno svih N-terminalnih amino kiselina do gly-ser regije, uklanjanje svih ili dijela N-terminalnih prolinom bogatih ponavljanja, ili oboje.
The pharmaceutical composition of unit dose according to claim 2, in which the ratio of the weight of the topical corticoid to the weight of the quinolone or the fusidic acid is between 0.5 and 1.5, and the amount of quinolone or fusidic acid is between 70 and 150 ug. 
3. Farmaceutski sprej pripravak prema zahtjevu 2, gdje je omjer težine topikalnog kortikoida prema težini kinolona ili fuzidične kiseline između 0.5 1 1.5 i količina kinolona ili fuzidične kiseline je između 70 i 150 ug.
According to the present invention, the concentration of said at least one aldehyde and/or at least one ketone in said fluid may be at least 100 part per million by weight, such as at least 250 part per million by weight, and preferably at least 400 parts per million by weight, such as at least 500 parts per million by weight. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 48-50, pri čemu je koncentracija navedenog barem jednog aldehida i/ili ketona u navedenoj tekućini najmanje 100 dijelova na milijun prema težini, kao što je najmanje 250 dijelova na milijun prema težini, a poželjno najmanje 400 dijelova na milijun prema težini, kao što je 500 dijelova na milijun prema težini.
The liquefied gas treatment system according to claim 7 or 8, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all or part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
An ultrasonically detectable intrauterine system (IUS) for long-term insertion into a uterine cavity, said IUS comprising a T-shaped plastic body and a hormone containing capsule placed in the vertical arm of the T-shaped plastic body, the vertical arm comprising at its lower end a loop wherein removal threads are tied, characterized in that the IUS comprises at least one image enhancing means for improving the ultrasound imaging of the system, wherein the at least one image enhancing means is at least one silver ring fixedly positioned and at least partly embedded in the body of the intrauterine system. 
PATENTNI ZAHTJEVI Ultrazvučno prepoznatljiv intrauterini sustav (IUS) za dugotrajno umetanje u šupljinu maternice, navedeni IUS sadrži plastično tijelo T-oblika i hormon koji sadrži kapsula postavljena u okomiti krak plastičnog tijela T-oblika, te okomiti krak sadrži na svojoj donjoj strani petlju pri čemu su vezice za uklanjanje vezane, naznačen time što IUS sadrži najmanje jedno sredstvo za poboljšanje slike radi poboljšanja ultrazvučnog snimanja sustava, pri čemu najmanje jedno sredstvo za poboljšanje slike je barem jedan srebrni prsten koji je fiksno smješten i barem djelomično ugrađen u tijelo intrauterinog sustava.
degradation of the polymer by enzymatic cleavage in the gastrointestinal tract, wherein the microspheres comprise a polysaccharide or a protein; 
(1i) degradacijom polimera enzimatskim cijepanjem u gastrointestinalnom traktu, pri čemu mikrosfere sadrže polisaharid ili protein;
The nasal cannula of claim 5, wherein the nasal cannula delivers one or more of the nitric oxide and the oxygen gases to the patient for treatment of at least one of pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), pulmonary hypertension as pulmonary arterial hypertension (PAH), pulmonary hypertension secondary to idiopathic pulmonary fibrosis (IPF), and pulmonary hypertension secondary to sarcoidosis. 
Nosna kanila iz bilo kojeg od patentnih zahtjeva 1-4, koja je konfigurirana za uporabu u liječenju najmanje jednog stanja između plućne hipertenzije sekundarne na kroničnu opstruktivnu plućnu bolest (COPD), plućne hipertenzije kao plućne arterijske hipertenzije (PAH), plućne hipertenzije sekundarne na idiopatsku plućnu fibrozu (IPF) i plućne hipertenzije sekundarne na sarkoidozu.
Ethyl acetate (4.5 mL) and glacial acetic acid (1.5 mL) was added followed by 10% Pd/C (0.5 g). 
Etil acetat (4.5 ml) i ledena octena kiselina (1.5 ml) se dodaju, a to je praćeno dodatkom 10% Pd/C (0.5 g).
A further advantage of this is thus that when the dispensing valve is placed in a dispensing tap as described the beverage content of the container need not come into contact with any reusable parts, that needs cleaning, and may infect the beverage. 
Daljnja prednost toga je da kad se ventil za točenje stavi u pipac za točenje, kako je opisano, piće koje se nalazi u spremniku ne mora doći u dodir s nijednim dijelom predviđenim za ponovnu upotrebu i koji se stoga mora čistiti, i koji može štetno djelovati na piće.
A pharmaceutical combination of Claim 25 wherein the lipid-modulating agent is a cholesteryl transfer protein inhibitor selected from CP-529,414; SC-744; SC-795; CETi-1; and JTT-705. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je sredstvo za modulaciju lipida inhibitor proteina za prijenos kolesterila odabran od CP-52 9,414, SC-744, SC-795, CETi-I i JTT-705.
The pharmaceutical composition of at least one of the items 1-11 for use in treating at least one metabolic syndrome and/or atherosclerosis. 
Farmaceutski pripravak za uporabu prema barem jednom od zahtjeva 1-11, naznačen time što dijabetes je dijabetes tipa 2.
An inhalation device according to claim 1 and 3, wherein the shape of the end of the drive gear (12a) that is connected to the mouthpiece cover (2) is different from the shape of the other end of the drive gear (12b). 
4. Uređaj za inhaliranje prema zahtjevu 1 1 3, naznačen time da je oblik završetka pogonskog zupčanika (124) koji je spojen na poklopac nastavka za usta (2) različit od oblika drugog završetka pogonskog zupčanika (12b).
Use of a hydroxypropyl cellulose for coating a tablet, the hydroxypropyl cellulose having a content of hydroxypropyl groups within a range of 42 to 48% by mass. 
Uporaba hidroksipropilceluloze, naznačena time, da je za oblaganje tablete, pri čemu hidroksipropilceluloza ima sadržaj hidroksipropil-skupina u rasponu od 42 do 48 masenih postotaka.
wherein R1 is selected from the group consisting of OR2 and NR3R4, and R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, and arylalkyl. 
HR P20100218 T1 gdje R, se bira iz skupine koju čine OR> i NR:R., gdje svakog od R2, Ra i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
The drug delivery device of claim 22 in which the conditioning and priming conditions include the use of an aqueous medium when the at least one active ingredient is hydrophilic. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 22, naznačen time što uvjeti podešavanja 1 početnog punjenja obuhvaćaju primjenu vodene podloge kada je najmanje jedan aktivni sastojak hidrofilan.
is C1-C4 linear alkyl or C3-C4 branched alkyl; or a pharmaceutically acceptable salt thereof. 
R je C,-Ca nerazgranati alkil ili C3-Ca razgranati alkil; ili njegova farmaceutski prihvatljiva sol.
The amber oil was used in the next step without purification. 
Jantarno ulje je uporabljeno u sljedećem koraku bez pročišćavanja.
positioning the first water vehicle at a location destination separated from a point of embarkation; and transporting by way of a second water vehicle a group of the plurality of passengers between the point of embarkation and the first water vehicle at the location destination. 
Metoda iz zahtjeva 9, koju nadalje čini: pozicioniranje plovila (100) na mjesto odredišta odvojeno od mjesta ukrcaja; i prijevoz drugim plovilom pluraliteta putnika između mjesta ukrcaja i plovila na odredištu.